Enlivex Ltd. (ENLV) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, ENLV scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: the Fundamental Cash Engine scores 4 of 20 (ROIC -0.6%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale/13F Flow scores 8 of 20 (institutional accumulation and options positioning), a weak institutional signal. Insider Conviction scores 5 of 20 (SEC Form 4 and Congressional PTR cluster flow), reflecting limited insider-driven confidence. Macro Regime Fit scores 9 of 20 (Beta 1.0; sector sensitivity), a middling sensitivity profile. Forensic Balance Sheet scores 10 of 20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5), which points to a balance sheet with moderate but not strong financial health signals.

For a prospective investor, the implications are primarily about downside risk and the absence of a cash-generation floor. With no reported revenue, negative operating income in every reported period, and a market capitalization of $3.9M against a 52-week range of $0.17 to $27.15, the stock's valuation is highly sensitive to sentiment, financing, and corporate actions rather than to earnings. Any upside case would have to rest on events outside the fundamental cash engine, such as clinical or corporate catalysts, which the source data does not quantify. Valuation multiples such as P/E and EV/EBITDA are not available in the source data, so a relative valuation tradeoff cannot be assessed.

Per the SEC financials, operating income was negative in every period shown, and free cash flow was negative throughout. The FY 2025 net income figure of $1235.5M is sharply inconsistent with its negative operating income of $-15.0M and is not explained in the source data; it should be treated with caution. Gross, operating, and net margins are all reported as 0%, and ROIC is -0.6%, per the market data. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, per the Roarable RQD rating; Debt/Equity is 0.5. Cash declined from $3.3M to $1.9M between FY 2024 and FY 2025. Debt is Not available in source data for any period.

• Reverse split (MARKET WIRE): A 1-for-16 reverse stock split was announced, effective October 27, 2026, with split-adjusted trading beginning that day after shareholder approval (per the Quiver Quantitative and Stock Titan items).
• Workforce and compensation cuts (RISK WATCH, RED): Reporting indicates jobs and CEO pay face cuts ahead of the company's next knee arthritis trial readout (per the Stock Titan item).
• General market coverage (MARKET WIRE, YELLOW): Multiple aggregator items reference ENLV stock price, forum discussion, and general positioning without specific fundamental content.
• Proprietary signals: None, per the Butterfly Supply-Chain Graph.

The reverse split and cost-reduction items are the most consequential catalysts in the feed. The RISK WATCH item signals operational contraction ahead of a clinical readout, which is a binary event whose outcome is not described in the source data.

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations beyond the broad Health Care and Biotechnology classification. For a prospective investor, the main second-order watch item is the knee arthritis trial readout referenced in the news feed: its result, timing, and any financing consequences are not resolved in the source data. The reverse split may also affect share count, liquidity, and perceived price levels, though the source data does not quantify these effects.

• What is the company's product pipeline and the regulatory status of the knee arthritis program referenced in the news feed?
• What explains the FY 2025 net income of $1235.5M alongside an operating loss of $-15.0M, and is that figure reliable?
• What is the company's debt position and runway, given that debt is unreported and cash fell to $1.9M?
• What are the terms and dilution implications of the 1-for-16 reverse split and any associated financing?
• What is the outcome and timing of the next clinical trial readout, and what would the financial impact be under each result?